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OBJECTIVE—The G-protein–coupled receptor GPR40 is ex-
pressed in pancreatic -cells and is activated by long-chain fatty
acids. Gene deletion studies have shown that GPR40 mediates, at
least in part, fatty acid–ampliﬁcation of glucose-induced insulin
secretion (GSIS) but is not implicated in GSIS itself. However,
the role of GPR40 in the long-term effects of fatty acids on insulin
secretion remains controversial. This study aimed to test the
hypothesis that GPR40 plays a role in insulin secretion after
high-fat feeding.
RESEARCH DESIGN AND METHODS—GPR40 knockout
(KO) mice on a C57BL/6 background and their wild-type (WT)
littermates were fed a high-fat diet (HFD) for 11 weeks. Glucose
tolerance, insulin tolerance, and insulin secretion in response to
glucose and Intralipid were assessed during the course of the diet
period.
RESULTS—GPR40 KO mice had fasting hyperglycemia. They
became as obese, glucose intolerant, and insulin resistant as their
WT littermates given HFD and developed a similar degree of liver
steatosis. Their fasting blood glucose levels increased earlier
than those of control mice during the course of the HFD. The
remarkable increase in insulin secretory responses to intrave-
nous glucose and Intralipid seen in WT mice after HFD was of
much lower magnitude in GPR40 KO mice.
CONCLUSIONS—GPR40 plays a role not only in fatty acid
modulation of insulin secretion, but also in GSIS after high-fat
feeding. These observations raise doubts on the validity of a
therapeutic approach based on GPR40 antagonism for the treat-
ment of type 2 diabetes.
F
atty acids do not initiate insulin release in the
absence of glucose, but they potentiate glucose-
induced insulin secretion (GSIS) upon acute ex-
posure. Their mechanisms of action are,
however, incompletely understood. The discovery of
GPR40 as a G-protein–coupled receptor highly expressed
in pancreatic -cells and activated by long-chain fatty
acids (1–4) has enabled the identiﬁcation of a novel
mechanism of action of fatty acids on insulin secretion.
Loss of function of GPR40 via small interfering RNA
(2,5–7), antisense oligonucleotides (8), pharmacological
inhibitors (9), or gene deletion in the mouse (10,11)
partially suppresses fatty acid potentiation of GSIS in
vitro. We (10) and others (11) have shown that whole-body
GPR40 knockout (KO) mice have normal glucose toler-
ance and unaltered insulin secretion in response to glu-
cose in vivo and in vitro, but that isolated islets from these
mice secrete less insulin in response to fatty acids. Fur-
thermore, insulin secretion induced by Intralipid in vivo is
reduced in GPR40 KO mice, demonstrating a physiological
role for GPR40 in fatty acid–potentiation of GSIS (10).
GPR40 has received considerable attention as a poten-
tial therapeutic target in type 2 diabetes (12–15). Surpris-
ingly, whether an agonist or antagonist should be
developed as a therapeutic agent remains debated (13,15).
This uncertainty stems, in part, from conﬂicting reports
regarding the role of GPR40 in -cell function (10,11).
Steneberg et al. (11) found that islets isolated from GPR40
KO mice were protected from the inhibitory effects of
prolonged fatty acid exposure on GSIS, in contrast to our
ﬁndings in a different line of GPR40 KO mice (10) and a
recent study using GPR40 agonists (16). Steneberg et al.
(11) further showed that GPR40 KO mice were protected
from high-fat diet (HFD)-induced insulin resistance, glu-
cose intolerance, and hepatic steatosis. Given these dis-
crepancies and the importance of determining whether an
agonist or antagonist approach should be pursued for drug
development, the present study was designed to test the
hypothesis that GPR40 contributes to the enhancement of
insulin secretion after HFD. Speciﬁcally, we sought to
examine whether GPR40 KO mice are more susceptible to
HFD-induced hyperglycemia and, if so, whether this is due
to changes in insulin secretion in vivo or associated with
changes in the expression of genes controlling fatty acid
metabolism in islets.
RESEARCH DESIGN AND METHODS
Reagents were from the following sources: 50% dextrose was from McKesson
Canada (Montre ´al, Canada), 0.9% saline was from Baxter (Mississauga,
Canada), and Intralipid was from Fresenius Kabi (Uppsala, Sweden). All other
reagents were from Sigma (St. Louis, MO) unless otherwise noted.
GPR40 KO mice were generated as described (10) and backcrossed to the
C57BL/6 strain for more than seven generations at Amgen (San Francisco,
CA). Animals were housed under controlled temperature conditions (21°C)
and a 12-h light/dark cycle with free access to food and water. At 7 weeks of
age, male GPR40 KO and wild-type (WT) littermates were fed either high-fat
(60% fat, 16% protein, and 24% carbohydrate on a caloric basis [#F3282;
Bioserv Diets, Frenchtown, NJ]) or regular (23% fat, 17% protein, and 60%
carbohydrates on a caloric basis [#2018; Harlan Teklad, Madison, WI]) diet.
Mice were housed individually, and body weight and food intake were
determined weekly. All procedures using animals were approved by the
institutional committee for the protection of animals at the Centre Hospitalier
de l’Universite ´ de Montre ´al.
Assessment of glucose homeostasis and insulin secretion. Fasting blood
glucose was measured weekly. Oral glucose tolerance was assessed in
overnight-fasted animals after administration of 1 g/kg glucose by gavage (10).
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2432 DIABETES, VOL. 57, SEPTEMBER 2008Insulin tolerance was measured in 5-h fasted animals after intraperitonial
administration of 1 unit/kg human insulin (10). For measurements of insulin
secretion in vivo, a catheter was inserted into the right jugular vein under
general anesthesia. Insulin secretion in response to intravenous glucose (0.5
g/kg) or Intralipid (100 l of a 20% solution preceded by 30 units of heparin)
was measured as described (10).
Tissue harvesting and histology. Mice were killed after 12 weeks of diet,
and islets were isolated as described (10). Livers were snap-frozen in liquid
nitrogen, embedded in OCT, prefrozen in anhydrous ethyl alcohol (100%
ethanol), and stained with Oil Red O.
Gene expression studies. Total RNA was extracted from 150 islets, and
RT-PCR was carried out using the QuantiTect SYBR Green PCR kit (Qiagen)
as described (17). Results are expressed as the ratio of target mRNA to -actin
mRNA and normalized to the levels in islets from regular diet–fed WT mice,
arbitrarily set as 1.
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FIG. 1. Fasting blood glucose levels of GPR40 KO and WT mice before
(A) and during (B) feeding a high-fat (HF) or regular diet (RD). *P <
0.05.
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FIG. 2. A: Glucose levels during oral glucose tolerance tests (OGTTs)
after 8 weeks of HFD; n  10–11 mice per group. B: Glucose levels
during intraperitoneal insulin tolerance tests (IPITTs) after 9 weeks
of HFD; n  8–10 mice per group. C: Oil Red O staining of liver sections
of KO and WT mice fed regular diet (RD) or HFD. Images are repre-
sentative of 3–4 animals in each group. (Please see http://dx.doi.org/
10.2337/db08-0553 for a high-quality digital representation of this
ﬁgure.)
TABLE 1
Metabolic parameters of GPR40 knockout and wild-type mice fed regular diet or HFD and gene expression levels in islets
WT-RD WT-HFD KO-RD KO-HFD
Weight gain (g) 6.1  0.7 14.5  1.3* 5.6  0.8 11.5  1.9*
Food intake (kcal  g
1  day
1) 0.58  0.02 0.64  0.05 0.61  0.02 0.62  0.05
Subcutaneous fat (g) 0.19  0.02 1.12  0.13* 0.11  0.02 0.84  0.16*
Infra-renal fat (g) 0.04  0.00 0.39  0.07* 0.03  0.00 0.29  0.06*
Brown adipose tissue (g) 0.07  0.01 0.15  0.02* 0.11  0.01 0.20  0.05*
AUCglucose OGTT week 8 11,715  1,104 18,517  1,612* 13,183  1,496 17,847  997*
AUCglucose IVGTT week 10 12,613  1,491 19,024  2,445* 10,949  1,049 15,348  3,189*
GPR40 mRNA 1.0  0.2 0.4  0.2 ND ND
GPR120 mRNA 1.0  0.4 0.7  0.3 1.3  0.4 0.7  0.2
CD36 mRNA 1.0  0.3 1.4  0.2 5.2  0.4† 2.6  0.5
CPT-1 mRNA 1.0  0.2 0.9  0.2 6.7  1.0† 1.1  0.2
Data are means  SE. n  9–12 animals per group. AUC, area under the curve; IVGTT, intravenous glucose tolerance test; ND, not
determined; OGTT, oral glucose tolerance test; RD, regular diet. *P  0.05 vs. RD; †P  0.05 vs. WT.
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measured enzymatically (Wako Chemicals, Neuss, Germany). Plasma insulin
was measured using a mouse ELISA kit (Alpco Diagnostics, Salem, NH).
Expression of data and statistics. Data are expressed as means  SE.
Intergroup comparisons were performed by ANOVA with post hoc adjust-
ments for 2-by-2 comparisons or Student’s t test where appropriate. P  0.05
was considered signiﬁcant. In Table 1 and Fig. 3, glucose clearance and insulin
secretion are expressed as the area under the curve, calculated above basal
values, and expressed as arbitrary units.
RESULTS AND DISCUSSION
Metabolic characteristics of GPR40 KO mice on a
C57BL/6 background. Seven-week-old GPR40 KO mice
on a C57BL/6 background had body weight similar to that
of their WT littermates (22.5  0.9 vs. 21.6  0.9 g; n  10
for each; P  NS) but showed fasting hyperglycemia
(135.8  5.3 vs. 115.4  4.1 mg/dl; n  19–22 per group;
P  0.05; Fig. 1A). Glucose and insulin tolerance were
similar in GPR40 KO and WT mice at 7 weeks of age
(supplementary Fig. S1, available in an online appendix at
http://dx.doi.org/10.2337/db08-0553). Thus, on a pure
C57BL/6 background, deletion of GPR40 leads to fasting
hyperglycemia despite normal glucose and insulin toler-
ance, suggesting that GPR40 contributes to the mainte-
nance of blood glucose levels during fasting. In the fasting
state, circulating levels of fatty acids increase and the
-cell uses fatty acids as its main energy source, with a
corresponding increase in fatty acid oxidation (18). Our
results therefore suggest that GPR40-mediated fatty acid
signaling contributes to the maintenance of basal insulin
secretion—and thereby normoglycemia—during fasting.
Effects of HFD on glucose and insulin tolerance in
GPR40 KO mice. Body weight, fat pad weight (white and
brown adipose tissue), and food intake increased to sim-
ilar levels in GPR40 KO and WT mice under HFD (Table 1).
As expected, WT mice developed fasting hyperglycemia
after 8 weeks of HFD. Fasting blood glucose increased
earlier in GPR40 KO mice during the course of the HFD
(Fig. 1B). Thus, after 3 weeks on diet, blood glucose levels
of the KO mice on HFD were signiﬁcantly higher than
those on regular diet (123.8  5.2 vs. 101.9  5.8 mg/dl;
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FIG. 3. A and B: Insulin levels in response to intravenous glucose after 10 weeks of regular diet (RD) (A) or HFD (B). C and D: Area under the
curve (AUC) for insulin over the ﬁrst 10 min (C) and from 10–60 min (D) following glucose injection. Values are expressed as means  SE of
8–10 mice per group. E and F: Insulin levels in response to intravenous Intralipid after 11 weeks of regular diet (E) or HFD (F). G and H: Area
under the curve for insulin for the ﬁrst 10 min (G) and from 10–60 min (H) following Intralipid injection. Values are expressed as means  SE
of 6–8 mice per group. *P < 0.
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2434 DIABETES, VOL. 57, SEPTEMBER 2008n  8–11 per group; P  0.006), whereas WT mice on HFD
and regular diet had similar blood glucose values (102.5 
3.5 vs. 93.3  1.7 mg/dl, n  10–11 per group; P  0.08).
Both GPR40 KO and WT animals were hyperglycemic after
8 weeks of HFD. Oral and intravenous glucose tolerance
were impaired to a similar extent in WT and KO mice after
HFD (Fig. 2A and Table 1) compared with mice on regular
diet (supplementary Fig. S2A). Similarly, the glucose-
lowering effect of insulin was reduced to the same extent
in both genotypes on HFD (Fig. 2B) compared with mice
on regular diet (supplementary Fig. S2B). Liver steatosis
developed in all animals examined of both genotypes
under HFD (Fig. 2C). Thus, GPR40 KO mice on a C57BL/6
background have fasting hyperglycemia that is further
aggravated during HFD. Furthermore, HFD in both GPR40
KO mice and their WT littermates is associated with
insulin resistance and glucose intolerance. Although we
have not performed euglycemic-hyperinsulinemic clamps
to directly measure insulin sensitivity, the observed de-
crease in the glucose-lowering effects of insulin, combined
with the presence of liver steatosis, indicate that GPR40
KO mice were not protected from the development of
insulin resistance during HFD. We suspect that the dis-
crepancies between our results and those of Steneberg et
al. (11) might be related to the genetic background of the
mice, an important determinant of susceptibility to glu-
cose intolerance (19). The mice used by Steneberg et al.
(11) were of a mixed background as opposed to the
C57BL/6 background used in the present study.
Effects of HFD on insulin secretion in GPR40 KO
mice. To examine whether GPR40 plays a role in insulin
secretion after HFD, we measured insulin release in re-
sponse to glucose and Intralipid after 10 and 11 weeks,
respectively, of HFD or regular diet. Insulin secretion in
response to intravenous glucose was similar in regular
diet–fed GPR40 KO and WT mice (Fig. 3A, C, D). After
administration of HFD, the second-phase insulin secretion
to intravenous glucose was greatly enhanced in WT mice
(Fig. 3B and D), and this increase was signiﬁcantly blunted
in GPR40 KO mice (Fig. 3B and D). These results suggest
that GPR40 becomes rate-limiting for GSIS after HFD.
These ﬁndings are consistent with the observation that
enhancement of intracellular lipid signaling plays a role in
-cell compensation for insulin resistance (20). Interest-
ingly, the marked differences in GSIS between GPR40 KO
and WT mice after HFD were not accompanied by changes
in glucose clearance, which is in keeping with the notion
that glucose clearance after an intravenous load in mice is
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(21,22).
As shown in Fig. 3E and G, GPR40 KO mice on a
C57BL/6 background have reduced insulin secretion in
response to Intralipid, as previously shown in mice on a
mixed background (23). Thus, ﬁrst-phase insulin secretion
was lower in GPR40 KO mice in response to Intralipid
compared with WT littermates (6.72  1.59 vs. 11.10  1.47
AU; n  6–7; P  0.05). After 11 weeks on HFD, WT mice
had a markedly increased response to intravenous In-
tralipid compared with that of regular diet–fed mice (Fig.
3F–H). In contrast, the increase in ﬁrst-phase insulin
release in response to Intralipid after HFD was markedly
reduced in GPR40 KO mice (Fig. 3F–H). These ﬁndings
show that GPR40 not only plays a role in insulin secretion
in response to fatty acids under basal conditions but is
essential for the -cell to mount a compensatory increase
in insulin secretion in response to both glucose and fatty
acids in the face of HFD-induced insulin resistance.
Effects of HFD on gene expression in GPR40 KO
mice. To gain insight into the molecular basis for the role
of GPR40 in insulin secretion, mRNA levels of genes
involved in fatty acid transport and metabolism were
measured in islets from GPR40 KO and WT mice after HFD
or regular diet (Table 1). GPR120 is another receptor for
long-chain fatty acids expressed in enteroendocrine cells
(23). We found GPR120 mRNA to be expressed in isolated
mouse islets, although its expression did not increase in
compensation for the absence of GPR40 in GPR40 KO
islets (Table 1). CD36 is a fatty acid transport protein that
plays an important role in fatty acid uptake and fatty acid
potentiation of GSIS (24). Carnitine palmitoyl trans-
ferase-1 (CPT-1) catalyzes the rate-limiting step in fatty
acid oxidation, i.e., transport of long-chain acyl-CoAs
across the mitochondrial membrane (25). GPR40 KO mice
on regular diet displayed an approximate ﬁve and seven-
fold increase in islet CD36 and CPT-1 mRNA expression,
respectively, compared with WT islets (Table 1), suggest-
ing an attempt to compensate for the absence of GPR40 by
enhancing fatty acid transport and intracellular metabo-
lism. Although expression of neither CD36 nor CPT-1 was
signiﬁcantly affected by HFD in WT animals, in KO islets
the increase in CD36 and CPT1 gene expression was
markedly reduced by HFD. This suggests that enhanced
expression of CD36 and CPT1 perhaps contributes to
the maintenance of normal glucose tolerance despite the
absence of GPR40 under basal conditions, but that the
absence of such an increase under HFD results in an
inability of the mice to sustain normal GSIS.
GPR40 KO mice on a C57BL/6 background have fasting
hyperglycemia and are not protected from HFD-induced
insulin resistance, and GPR40 is implicated not only in
insulin secretion in response to fatty acids but also in GSIS
after HFD. These ﬁndings suggest that the mechanisms by
which the -cell mounts a compensatory response to
HFD-induced insulin resistance involve, at least in part,
signaling through GPR40. As such, our results raise doubts
on the validity of a therapeutic approach based on GPR40
antagonism for the treatment of type 2 diabetes.
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